
Speakers At WIPO Diverge On Patents-Access Relationship; Biologics A Challenge For Generics
A seminar on patents and availability of medicines in developing countries yesterday considered whether patents constitute a barrier to access. For the private sector, patents are essential to the innovation system, for others they maintain high prices and should be licensed for easier access. Beyond patents, biologics seem to be taking over the pharmaceutical industry, and the complexity of manufacturing biosimilars might well leave traditional generic manufacturers by the wayside.
Separately, a side event at WIPO looked at IP management strategies in private-public partnerships in agriculture and health technologies.






